Journal article
Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Cancer epidemiology, biomarkers & prevention, Vol.24(10), pp.1507-1515
10/2015
DOI: 10.1158/1055-9965.EPI-15-0394
PMCID: PMC4592455
PMID: 26269564
Abstract
Findings from epidemiologic studies examining associations of serum retinol and carotenoids with prostate cancer risk have been inconsistent. This case-control study nested in the Prostate Cancer Prevention Trial evaluated associations of serum retinol and carotenoids with total, low-, and high-grade prostate cancer risk in a highly screened study population.
We used logistic regression adjusting for age, family history of prostate cancer, race, body mass index, and serum cholesterol to estimate ORs and 95% confidence intervals (CI) of prostate cancer by quartiles of serum retinol and carotenoids, separately in the placebo (975 cases/1,009 frequency-matched controls) and finasteride (708 cases/743 frequency-matched controls) arms of the trial.
Serum retinol concentrations were associated with increased risk of total prostate cancer [OR (95% CI) comparing the highest quartile of serum retinol with the lowest: 1.30 (1.00-1.68)] and high-grade prostate cancer [OR (95% CI), 1.74 (1.14-2.68)] in the placebo arm of the trial only. Also in the placebo arm, there was a moderate positive association of α-carotene with risk of total prostate cancer [OR (95% CI), 1.32 (1.01-1.73)]. None of the other carotenoids was associated with prostate cancer risk in the placebo arm. No associations were observed for retinol and carotenoids in the finasteride arm.
In the placebo arm of this prospective study, high serum retinol and α-carotene concentrations were associated with increased risk of total and high-grade prostate cancers.
Men with higher levels of serum retinol and α-carotene may be at increased risk for prostate cancer.
Details
- Title: Subtitle
- Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
- Creators
- Sarah H Nash - Cancer Prevention Fellowship Program, Division of Cancer Prevention, National Cancer Institute, Bethesda, MarylandCathee Till - SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WashingtonXiaoling Song - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WashingtonM Scott Lucia - Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Denver, ColoradoHoward L Parnes - Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MarylandIan M Thompson Jr - Department of Urology, School of Medicine, University of Texas Health Science Center, San Antonio, TexasScott M Lippman - Office of the Director, Moores Cancer Center, University of California at San Diego, San Diego, CaliforniaElizabeth A Platz - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Department of Urology, and the James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MarylandJeannette Schenk - Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington. jschenk@fredhutch.org
- Resource Type
- Journal article
- Publication Details
- Cancer epidemiology, biomarkers & prevention, Vol.24(10), pp.1507-1515
- DOI
- 10.1158/1055-9965.EPI-15-0394
- PMID
- 26269564
- PMCID
- PMC4592455
- ISSN
- 1055-9965
- eISSN
- 1538-7755
- Grant note
- UG1 CA189974 / NCI NIH HHS U10 CA037429 / NCI NIH HHS U10 CA37429 / NCI NIH HHS UM1 CA182883 / NCI NIH HHS U10 CA180834 / NCI NIH HHS P01 CA108964 / NCI NIH HHS
- Language
- English
- Date published
- 10/2015
- Academic Unit
- Epidemiology; Center for Social Science Innovation
- Record Identifier
- 9984214783902771
Metrics
21 Record Views